Author: CHPI Annual Report
The cost of patented drugs is often cited to justify the regulation of pharmaceutical markets and to restrict public and private insurance coverage of new medicines. The objective of this annual CHPI study is to establish the facts about the specific impact of patented drugs on the cost of health care in Canada.
